Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Amprolium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | SLC19A2 | O60779 | 1/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | F11 | P03951 | 2/20 | 0.33 |
| ▸ | F7 | P08709 | 2/20 | 0.33 |
| ▸ | F3 | P13726 | 2/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amprolium Ion SCHEMBL28047744 | 0.77 | KDM4E (0.98) | TDP1LMNAUSP2KDM4ESLC19A2 | |
| Amprolium Ion SCHEMBL363586 | 0.76 | KDM4E (0.95) | TDP1LMNAUSP2KDM4ESLC19A2 | |
| Amprolium Ion SCHEMBL20659804 | 0.75 | KDM4E (0.98) | TDP1LMNAUSP2KDM4ESLC19A2 | |
| Amprolium Ion SCHEMBL204024 | 0.75 | KDM4E (0.98) | TDP1LMNAUSP2KDM4ESLC19A2 | |
| Ethopabate SCHEMBL29625103 | 0.71 | TDP1 (1.00) | TDP1LMNAKDM4ECASP1ALDH1A1 | |
| Ethopabate SCHEMBL540932 | 0.71 | TDP1 (1.00) | TDP1LMNAKDM4ECASP1ALDH1A1 | |
| Ethopabate SCHEMBL28629644 | 0.70 | TDP1 (0.97) | TDP1LMNAKDM4ECASP1ALDH1A1 | |
| SCHEMBL21219501 | 0.66 | TDP1 (0.82) | TDP1LMNAKDM4ERORCSMN1; SMN2 | |
| Sulfaquinoxaline SCHEMBL8098708 | 0.65 | ATIC (0.62) | TDP1LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL28427762 | 0.65 | TDP1 (0.80) | TDP1LMNAKDM4ECASP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2700407-A1 | GRANULES IN LIQUID DOSAGE FORM | Idemitsu Kosan Co., Ltd (JP) | 2014-02-26 | — | — | EP | disclosed |
| US-20140030349-A1 | GRANULES IN LIQUID DOSAGE FORM | IDEMITSU KOSAN CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |